Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study

被引：0
|
作者：
William B. Young
J. Ivan Lopez
John F. Rothrock
Amelia Orejudos
Aubrey Manack Adams
Richard B. Lipton
Andrew M. Blumenfeld
机构：
[1] Jefferson Hospital for Neuroscience,
[2] University of South Alabama College of Medicine,undefined
[3] George Washington School of Medicine,undefined
[4] Allergan plc,undefined
[5] Montefiore Headache Center,undefined
[6] Department of Neurology,undefined
[7] Department of Epidemiology and Population Health,undefined
[8] Albert Einstein College of Medicine,undefined
[9] Headache Center of Southern California,undefined
[10] The Neurology Center,undefined
来源：
The Journal of Headache and Pain | 2019年 / 20卷
关键词：
COMPEL; Daily headache; Disability; Migraine; OnabotulinumtoxinA; Quality of life;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Clinically Meaningful Benefits of OnabotulinumtoxinA Beyond Headache Days in Chronic Migraine: Analysis of the COMPEL and Pooled PREEMPT Studies
    Blumenfeld, Andrew M.
    Diener, Hans-Christoph
    Lipton, Richard B.
    Dodick, David W.
    DeGryse, Ronald E.
    Adams, Aubrey Manack
    Silberstein, Stephen D.
    NEUROLOGY, 2020, 94 (15)
  • [42] Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study
    Blumenfeld, Andrew M.
    Stark, Richard J.
    Freeman, Marshall C.
    Orejudos, Amelia
    Adams, Aubrey Manack
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [43] Do patients with chronic migraine and daily headache respond to preventatives? Analysis of a series of 265 patients treated with Onabotulinumtoxina
    Hernandez, I.
    Gutierrez Sanchez de la Puente, M.
    Talavera de la Esperanza, B.
    Martinez Badillo, C.
    Garcia Iglesias, C.
    Sierra Mencia, A.
    Garcia Azorin, D.
    Guerrero Peral, A. L.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 614 - 614
  • [44] Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study
    Andrew M. Blumenfeld
    Richard J. Stark
    Marshall C. Freeman
    Amelia Orejudos
    Aubrey Manack Adams
    The Journal of Headache and Pain, 2018, 19
  • [45] The patients' perceptions of migraine and chronic daily headache: A qualitative study
    Peters M.
    Huijer Abu-Saad H.
    Vydelingum V.
    Dowson A.
    Murphy M.
    The Journal of Headache and Pain, 2005, 6 (1) : 40 - 47
  • [46] Patients' management of migraine, migraine with aura and chronic daily headache
    Peters, M
    Abu-Saad, HH
    Robbins, I
    Vydelingum, V
    Dowson, A
    Murphy, M
    CEPHALALGIA, 2003, 23 (07) : 751 - 751
  • [47] Efficacy, tolerability, and safety of onabotulinumtoxinA treatment for chronic migraine in patients with acute medication overuse: analysis of the PREEMPT and COMPEL trials
    Agosti, R.
    Straube, A.
    Diener, H. C.
    Freeman, M.
    Pascual Gomez, J.
    Seminerio, M.
    Delahaye, L.
    Stark, R. J.
    JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [48] OnabotulinumtoxinA Treatment in Chronic Migraine: Investigation of Its Effects on Disability, Headache and Neck Pain Intensity
    Onan, Dilara
    Bentivegna, Enrico
    Martelletti, Paolo
    TOXINS, 2023, 15 (01)
  • [49] Chronic migraine treatment: from OnabotulinumtoxinA onwards
    Negro, Andrea
    Curto, Martina
    Lionetto, Luana
    Giamberardino, Maria Adele
    Martelletti, Paolo
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2016, 16 (10) : 1217 - 1227
  • [50] Daily Headache in Chronic Migraine Is a Predictive Factor of Response in Patients Who Had Completed Three Sessions of OnabotulinumtoxinA
    Martinez-Pias, Enrique
    Guerrero, Angel L.
    Sierra, Alvaro
    Trigo, Javier
    Garcia-Azorin, David
    TOXINS, 2021, 13 (06)
12345